Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 5/20 | 0.40 |
| ▸ | JAK2 | O60674 | 3/20 | 0.40 |
| ▸ | FLT3 | P36888 | 3/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4052229 | 0.86 | KDM4E (0.50) | SYKKMT2ADHFRHDAC1CYP1A2 | |
| SCHEMBL4563099 | 0.85 | DHFR (0.37) | DHFRCDK4HDAC1 | |
| SCHEMBL1475609 | 0.80 | JAK3 (0.53) | SYKJAK2FLT3 | |
| SCHEMBL8339799 | 0.73 | KMT2A (0.57) | KMT2ANUDT1BACE1HDAC1CYP1A2 | |
| SCHEMBL29430433 | 0.72 | SLC2A1 (0.54) | SYKCYP1A2 | |
| SCHEMBL4469935 | 0.72 | SLC2A1 (0.54) | SYKCYP1A2 | |
| SCHEMBL4491222 | 0.70 | SCN9A (0.43) | SYKKMT2ANUDT1BACE1 | |
| SCHEMBL1473471 | 0.68 | SYK (0.51) | SYKJAK2FLT3 | |
| SCHEMBL11195213 | 0.68 | KMT2A (0.83) | KMT2ANUDT1BACE1CYP1A2TSHR | |
| SCHEMBL19527732 | 0.67 | NPC1 (0.49) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318687-A1 | Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-7560466-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070225495-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-7122542-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20050209224-A1 | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | MIDCAP FINANCIAL TRUST | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225495-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | SSB, TYMS, TPMT | SYK 2199/4885KMT2A 1472/4885NUDT1 38/4885 |
| US-20090318687-A1 | Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds | SSB, TYMS, TPMT | SYK 2199/4885KMT2A 1472/4885NUDT1 38/4885 |
| US-20050209224-A1 | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | SSB, TYMS, TPMT | SYK 2199/4885KMT2A 1472/4885NUDT1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.